Article Text

Download PDFPDF
EU news
Public consultation for European health data space is open
  1. Stephanie Kohl
  1. Policy & Advocacy, European Association of Hospital Pharmacists, Brussels 1200, Belgium
  1. Correspondence to Stephanie Kohl, Policy & Advocacy, European Association of Hospital Pharmacists, Brussels 1200, Belgium; Stephanie.Kohl{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The European Commission has launched a public consultation on the European Health Data Space (EHDS). Stakeholders are encouraged to share their comments until the 26th of July. The purpose of the EHDS is to promote health-data exchange and support research on new preventive strategies, as well as on treatments, medicines, medical devices and outcomes. The public consultation focuses on the access to and use of health data for healthcare provision, research and innovation, policy-making and regulatory decision and on fostering a genuine single market for digital health services and products, including innovative ones. By participating, you can provide important insights, opinions and evidence to support the impact assessment accompanying the EHDS proposal on the problems to be tackled, the policy options to be considered and their likely impacts.

Commission proposes EU strategy for the development and availability of therapeutics

In May, the European Commission released its strategy on COVID-19 therapeutics which aims at supporting the development and availability of much-needed treatment options, including those for ‘long COVID-19'. The strategy covers the full lifecycle of medicines ranging from research, development over manufacturing to procurement and deployment.

The Strategy proposes clear actions and targets, including authorising three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year. By next month, the European Commission will draw up a portfolio of 10 potential COVID-19 therapeutics to …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.